Literature DB >> 3139698

The luteal phase and early pregnancy after combined GnRH-agonist/HMG treatment for superovulation in IVF or GIFT.

J Smitz1, P Devroey, M Camus, J Deschacht, I Khan, C Staessen, L Van Waesberghe, A Wisanto, A C Van Steirteghem.   

Abstract

Endometrial biopsies showing inadequate development were observed after ovarian stimulation with the GnRH agonist Buserelin and HMG for IVF or GIFT when luteal supplementation was omitted. Ninety-one patients were randomly allocated to two luteal supplementation regimens: in 41 women HCG and in 50 women progesterone and oestradiol valerate. The pregnancy patients treated with a combination of the GnRH agonist and HMG a delay of implantation of 1.3 days was observed compared to pregnancies after clomiphene citrate-HMG stimulation. This delay was not due to slower preimplantation embryo development after GnRH agonist-HMG treatment. Temporarily defective function of the corpus luteum was evidenced by measuring serum progesterone, 17 beta-oestradiol and 17-hydroxyprogesterone in the patients receiving progesterone and oestradiol valerate. This inadequate corpus luteum function could be related to the prolonged blockage of pituitary gonadotrophic function after arrest of the GnRH agonist.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3139698     DOI: 10.1093/oxfordjournals.humrep.a136750

Source DB:  PubMed          Journal:  Hum Reprod        ISSN: 0268-1161            Impact factor:   6.918


  25 in total

Review 1.  Buserelin. A review of its pharmacodynamic and pharmacokinetic properties, and clinical profile.

Authors:  R N Brogden; M M Buckley; A Ward
Journal:  Drugs       Date:  1990-03       Impact factor: 9.546

2.  II. Cognitive performance of middle-aged female rats is influenced by capacity to metabolize progesterone in the prefrontal cortex and hippocampus.

Authors:  Jason J Paris; Alicia A Walf; Cheryl A Frye
Journal:  Brain Res       Date:  2010-10-31       Impact factor: 3.252

3.  Estradiol supplementation during the luteal phase in poor responder patients undergoing in vitro fertilization: a randomized clinical trial.

Authors:  Marzieh Aghahosseini; Ashraf Aleyassin; Sepideh Khodaverdi; Fatemeh Esfahani; Robabeh Mohammadbeigi; Shohreh Movahedi; Ali Kord Valeshabad; Atossa Mahdavi; Parvin Fallahi; Parisa Shabani; Zahra Rezaeeian; Maryam Khodaverdi
Journal:  J Assist Reprod Genet       Date:  2011-07-01       Impact factor: 3.412

4.  An 18-month survey of infertility treatment by in vitro fertilization, gamete and zygote intrafallopian transfer, and replacement of frozen-thawed embryos.

Authors:  C Staessen; M Camus; I Khan; J Smitz; L Van Waesberghe; A Wisanto; P Devroey; A C Van Steirteghem
Journal:  J In Vitro Fert Embryo Transf       Date:  1989-02

Review 5.  Potential use of embryo coculture with human in vitro fertilization procedures.

Authors:  J K Thibodeaux; R A Godke
Journal:  J Assist Reprod Genet       Date:  1995-11       Impact factor: 3.412

6.  Subpopulations of human granulosa-luteal cells obtained from gonadotropin- or gonadotropin-releasing hormone agonist/gonadotropin-treated follicles in in vitro fertilization-embryo transfer cycles.

Authors:  K Gersak; T Tomazevic
Journal:  J Assist Reprod Genet       Date:  1999-10       Impact factor: 3.412

Review 7.  Luteal phase support for assisted reproduction cycles.

Authors:  Michelle van der Linden; Karen Buckingham; Cindy Farquhar; Jan A M Kremer; Mostafa Metwally
Journal:  Cochrane Database Syst Rev       Date:  2015-07-07

8.  Association of controlled ovarian hyperstimulation treatment with down-regulation of key regulators involved in embryonic implantation in mice.

Authors:  Min Xiong; Hanwang Zhang; Lei Jin; Jihui Ai; Zhiyong Huang; Guijin Zhu
Journal:  J Huazhong Univ Sci Technolog Med Sci       Date:  2011-08-07

9.  A comparative, randomized study of three different progesterone support of the luteal phase following IVF/ET program.

Authors:  P G Artini; A Volpe; S Angioni; M C Galassi; C Battaglia; A R Genazzani
Journal:  J Endocrinol Invest       Date:  1995-01       Impact factor: 4.256

10.  Luteal Phase Support in assisted reproductive technology treatment: focus on Endometrin(R) (progesterone) vaginal insert.

Authors:  Jerome H Check
Journal:  Ther Clin Risk Manag       Date:  2009-06-04       Impact factor: 2.423

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.